DAVITA INC. (DVA) Quick Ratio
- Quick ratio · latest quarter: Value 1.11×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.11× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $3.16B ÷ $2.86B ≈ 1.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 3.16B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.86B USD | Liabilities, Current |
| Cash and equivalents | 668.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 19.91M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 2.47B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 151.53M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.16B | $2.86B | $668.96M | $19.91M | $2.47B | $151.53M | 1.11× |
| 2026-03-31 | $3.13B | $2.87B | $644.24M | $22.30M | $2.46B | $141.61M | 1.09× |
| 2025-12-31 | $3.12B | $3.14B | $676.44M | $24.30M | $2.41B | $160.63M | 0.99× |
| 2025-09-30 | $3.07B | $3.02B | $705.96M | $30.52M | $2.33B | $139.09M | 1.02× |
| 2025-06-30 | $3.18B | $2.93B | $708.42M | $31.01M | $2.44B | $146.29M | 1.08× |
| 2025-03-31 | $2.83B | $2.91B | $438.78M | $73.16M | $2.32B | $150.52M | 0.97× |
| 2024-12-31 | $2.99B | $2.97B | $794.93M | $51.06M | $2.15B | $134.56M | 1.01× |
| 2024-09-30 | $3.36B | $2.94B | $1.07B | $21.00M | $2.27B | $129.00M | 1.14× |
| 2024-06-30 | $2.74B | $2.99B | $416.49M | $20.69M | $2.30B | $126.77M | 0.92× |
| 2024-03-31 | $2.95B | $2.58B | $345.13M | $10.61M | $2.59B | $145.81M | 1.14× |
| 2023-12-31 | $2.38B | $2.64B | $380.06M | $11.61M | $1.99B | $143.10M | 0.90× |
| 2023-09-30 | $2.49B | $2.54B | $449.46M | $11.71M | $2.02B | $109.62M | 0.98× |
| 2023-06-30 | $2.35B | $2.40B | $327.44M | $12.48M | $2.01B | $110.30M | 0.98× |
| 2023-03-31 | $2.42B | $2.57B | $317.13M | $49.97M | $2.06B | $106.77M | 0.95× |
| 2022-12-31 | $2.45B | $2.62B | $244.09M | $77.69M | $2.13B | $109.12M | 0.94× |
| 2022-09-30 | $2.53B | $2.54B | $367.51M | $74.31M | $2.09B | $106.84M | 1.00× |
| 2022-06-30 | $2.46B | $2.31B | $262.61M | $100.49M | $2.09B | $109.52M | 1.06× |
| 2022-03-31 | $2.39B | $2.42B | $327.50M | $19.41M | $2.04B | $107.72M | 0.99× |
| 2021-12-31 | $2.44B | $2.40B | $461.90M | $22.31M | $1.96B | $107.43M | 1.02× |
| 2021-09-30 | $3.10B | $2.36B | $1.05B | $26.69M | $2.03B | $114.10M | 1.31× |
| 2021-06-30 | $3.03B | $2.39B | $1.04B | $36.70M | $1.95B | $115.37M | 1.27× |
| 2021-03-31 | $2.94B | $2.31B | $884.21M | $11.06M | $2.04B | $116.32M | 1.27× |
| 2020-12-31 | $2.17B | $2.48B | $324.96M | $20.10M | $1.82B | $111.63M | 0.88× |
| 2020-09-30 | $2.53B | $2.50B | $710.51M | $19.36M | $1.80B | $106.25M | 1.01× |
| 2020-06-30 | $4.86B | $4.27B | $2.93B | $154.12M | $1.77B | $97.90M | 1.14× |
| 2020-03-31 | $3.21B | $2.22B | $1.38B | $9.38M | $1.82B | $95.69M | 1.45× |
| 2019-12-31 | $2.91B | $2.37B | $1.10B | $11.57M | $1.80B | $97.95M | 1.23× |
| 2019-09-30 | $3.26B | $2.21B | $1.25B | $100.71M | $1.90B | $98.64M | 1.48× |
| 2019-06-30 | $5.59B | $5.71B | $3.58B | $5.21M | $2.01B | $96.82M | 0.98× |
| 2019-03-31 | $2.42B | $8.23B | $459.24M | $4.04M | $1.95B | $104.24M | 0.29× |
| 2018-12-31 | $2.18B | $4.89B | $323.04M | $2.94M | $1.86B | $107.38M | 0.45× |
| 2018-09-30 | $2.30B | $4.86B | $448.21M | $4.73M | $1.85B | $91.10M | 0.47× |
| 2018-06-30 | $2.24B | $4.78B | $389.26M | $4.53M | $1.84B | $112.73M | 0.47× |
| 2018-03-31 | $2.19B | $2.95B | $358.87M | $4.60M | $1.83B | $125.56M | 0.74× |
| 2017-12-31 | $2.27B | $3.04B | $508.23M | $43.52M | $1.71B | $181.80M | 0.75× |
| 2017-09-30 | $3.07B | $2.87B | $846.11M | $137.36M | $2.09B | $154.42M | 1.07× |
| 2017-06-30 | $2.98B | $2.77B | $712.00M | $211.44M | $2.05B | $199.30M | 1.07× |
| 2017-03-31 | $3.69B | $2.81B | $1.47B | $313.26M | $1.90B | $174.16M | 1.31× |
| 2016-12-31 | $3.14B | $2.70B | $913.19M | $310.20M | $1.92B | $164.86M | 1.16× |
| 2016-09-30 | $3.42B | $2.64B | $913.50M | $659.48M | $1.85B | $200.56M | 1.30× |
| 2016-06-30 | $3.55B | $2.65B | $1.28B | $394.17M | $1.88B | $197.39M | 1.34× |
| 2016-03-31 | $3.29B | $2.44B | $1.04B | $396.47M | $1.86B | $192.69M | 1.35× |
| 2015-12-31 | $3.63B | $2.40B | $1.50B | $408.08M | $1.72B | $185.57M | 1.51× |
| 2015-09-30 | $3.67B | $2.41B | $1.05B | $922.85M | $1.70B | $173.05M | 1.52× |
| 2015-06-30 | $3.54B | $2.33B | $933.74M | $942.14M | $1.67B | $159.35M | 1.52× |
| 2015-03-31 | (m) | $2.68B | $1.01B | (m) | $1.68B | $145.74M | (m) |
| 2014-12-31 | $2.83B | $2.09B | $965.24M | $337.40M | $1.53B | $136.09M | 1.35× |
| 2014-09-30 | (m) | $2.60B | $1.53B | (m) | $1.47B | $114.68M | (m) |
| 2014-06-30 | (m) | $2.61B | $1.42B | (m) | $1.55B | $99.65M | (m) |
| 2014-03-31 | (m) | $2.57B | $1.11B | (m) | $1.54B | $101.17M | (m) |
| 2013-12-31 | (m) | $2.46B | $946.25M | (m) | $1.49B | $88.81M | (m) |
| 2013-09-30 | (m) | $2.45B | $970.69M | (m) | $1.40B | $84.90M | (m) |
| 2013-06-30 | (m) | $2.21B | $617.90M | (m) | $1.45B | $78.00M | (m) |
| 2013-03-31 | (m) | $2.33B | $699.67M | (m) | $1.52B | $76.58M | (m) |
| 2012-12-31 | (m) | $2.02B | $533.75M | (m) | $1.42B | $78.13M | (m) |
| 2012-09-30 | (m) | $1.34B | $382.19M | (m) | $1.25B | $78.32M | (m) |
| 2012-06-30 | (m) | $1.24B | $273.44M | (m) | $1.25B | $77.68M | (m) |
| 2012-03-31 | (m) | $1.24B | $449.29M | (m) | $1.27B | $72.28M | (m) |
| 2011-12-31 | (m) | $1.15B | $393.75M | (m) | $1.20B | $75.73M | (m) |
| 2011-09-30 | (m) | $1.21B | $541.21M | (m) | $1.17B | $73.29M | (m) |
| 2011-06-30 | (m) | $1.04B | $729.83M | (m) | $1.13B | $68.63M | (m) |
| 2011-03-31 | (m) | $1.01B | $1.01B | (m) | $1.07B | $69.64M | (m) |
| 2010-12-31 | (m) | $924.35M | $860.12M | (m) | $1.05B | $76.01M | (m) |
| 2010-09-30 | (m) | $1.11B | $534.57M | (m) | $1.08B | $68.95M | (m) |
| 2010-06-30 | (m) | $1.12B | $574.72M | (m) | $1.07B | $69.39M | (m) |
| 2010-03-31 | (m) | $1.05B | $755.91M | (m) | $1.10B | $68.04M | (m) |
| 2009-12-31 | (m) | $1.05B | $539.46M | (m) | $1.11B | $70.04M | (m) |
| 2009-09-30 | (m) | $1.11B | $581.68M | (m) | $1.14B | $69.01M | (m) |
| 2009-06-30 | (m) | $1.11B | $544.11M | (m) | $1.13B | $65.35M | (m) |
| 2009-03-31 | (m) | (m) | $405.68M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $1.16B | $410.88M | (m) | $1.08B | $84.17M | (m) |
| 2008-09-30 | (m) | (m) | $387.95M | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $326.99M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $447.05M | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $310.20M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |